September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings. Prescription drug price comparison platform GoodRx...read more
PMV Pharmaceuticals, an early stage biotech developing targeted therapies for cancer, raised $212 million by offering 11.8 million shares at $18, the high end of the range of $16 to $18. The Cranbury, NJ-based company plans to list on the Nasdaq under the...read more
PMV Pharmaceuticals, a early stage biotech developing targeted therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The Cranbury, NJ-based company now plans to raise $200 million by offering 11.8 million shares at a price...read more
PMV Pharmaceuticals, an early stage biotech developing targeted therapies for cancer, announced terms for its IPO on Monday. The Cranbury, NJ-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the...read more
US IPO Weekly Recap: Health and tech dominate the calendar in an 11 IPO week
September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings. Prescription drug price comparison platform GoodRx...read more
Precision oncology biotech PMV Pharmaceuticals prices IPO at $18, the high end of the range
PMV Pharmaceuticals, an early stage biotech developing targeted therapies for cancer, raised $212 million by offering 11.8 million shares at $18, the high end of the range of $16 to $18. The Cranbury, NJ-based company plans to list on the Nasdaq under the...read more
Precision oncology biotech PMV Pharmaceuticals ups proposed deal size by 60% ahead of $200 million IPO
PMV Pharmaceuticals, a early stage biotech developing targeted therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The Cranbury, NJ-based company now plans to raise $200 million by offering 11.8 million shares at a price...read more
Precision oncology biotech PMV Pharmaceuticals sets terms for $125 million IPO
PMV Pharmaceuticals, an early stage biotech developing targeted therapies for cancer, announced terms for its IPO on Monday. The Cranbury, NJ-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the...read more